RednessNCT07200492
Anti-Redness Clinical Study
A study testing Facial serum application and Forearm serum application in people with Redness, run by ChinaNorm at 1 site in China.
Trial summary
This clinical study is a single-center, randomized, split-face, on-site controlled trial conducted at Shanghai China-Norm Quality Technical Service Co., Ltd. The primary objective is to evaluate the efficacy of Eucerin Ultrasensitive Repair Intensive Source Serum in providing instant and long-lasting (24-hour)… Read more about this study
- Who is it for?
- Ages 18 to 60 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Redness
- What is being tested?
- Facial serum application and Forearm serum application
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 1 siteChina
- Study dates
- 15 Jan 2024to 24 Jan 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Chinese female whose age range from 18 to 60 years old;
- Be in general good health and good mental state;
- Have no any broken,scars,birthmarks and other imperfections on the test area;
- Redness/erythema≥grade 2 after modelling inducing and the score of redness must be increased after inducing;
- Not currently be participating in any other study involving the test area(Face and Forearm);
- Not have participated in any other study involving the test area in the past one month;
- Be willing to read,understand and able to sign the Informed Consent Form and Photo Release From;
- Be willing to comply with all study protocol requirements.
Who cannot join
- Intending to get pregnant, be pregnant, be lactating, be within 6 months of delivery or be unwilling to take necessary precautions to avoid a pregnancy;
- Having used antihistamine drugs in the past 1 week or immunosuppressants in the past 1 month;
- Taken anti-allergic drug/injections in the past 1 month;
- Presently have allergies, allergic dermatitis or skin disease;
- Have sensitivity or even allergy to topical products, ingredients or fragranced products;
- Have history of allergies;
Show all 16Show fewer
- Have history of suffering from skin diseases (such as psoriasis, eczema, skin cancer, etc.);
- Have used any anti-inflammatory treatment on the test area within 2 months prior to this study starting date;
- Has a chronic medical condition that may interfere with testing (e.g., asthma, insulin-dependent diabetes, lupus, rheumatoid arthritis or other immune/auto-immune diseases);
- Have used any scrubs or peeling product (regardless of method) or self-tanning products or oil control products in the past 3 days;
- Have received cosmetic medical procedures on the face (such as injectable anti-wrinkle products, cosmetic surgery, tattoo removal, home light facial procedures or home use medical devices, etc.) in the past 1 month;
- Have excessive sun exposure or ultraviolet light exposure in the past 1 month;
- Have applied ortho-hydroxybenzoic acid, hydroquinone in the past 3 months; or used prescriptions (such as antibiotic, retinoids, alpha hydroxyl acid and steroid), oral contraceptives；
- Avoid providing emergency contact;
- Subjects that are not compliant with the selection criteria or not proper for participation as determined by Principal Investigator;
- An employee of the cosmetic companies or Shanghai China-Norm Quality technical service Co., Ltd.
Trial locations and contacts
1 site in 1 country.
China1 site
Shanghai China-norm Quality Technical Service Co., Ltd.
Shanghai, Shanghai Municipality, 200072
About this study
This clinical study is a single-center, randomized, split-face, on-site controlled trial conducted at Shanghai China-Norm Quality Technical Service Co., Ltd. The primary objective is to evaluate the efficacy of Eucerin Ultrasensitive Repair Intensive Source Serum in providing instant and long-lasting (24-hour) soothing and repairing effects under induced redness conditions. The design involves recruiting 30 healthy Chinese female subjects aged 18-60 years, who meet stringent inclusion/exclusion criteria, including absence of skin conditions and no recent participation in similar studies. Redness is induced using 50% Glycolic Acid on the entire face and tape stripping on both forearms.
- Conditions
- Redness
- Being tested
- Facial serum application, Forearm serum application
- Medical subject headings
- Erythema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Facial serum applicationOther
The trained technician will apply the 0.3g-0.4g investigational products on the subject's half face.
Forearm serum applicationOther
The trained technician will apply the (2mg±0.1mg)/cm² investigational products on the subject's forearm.
| Study group | Role | What they receive |
|---|---|---|
| Facial Test Arm | Other | Not described Receives: Other: Facial serum application |
| Facial Control Arm | No intervention | Not described |
| Arm Test Arm | Other | Not described Receives: Other: Forearm serum application |
| Arm Control Arm | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Skin Erythema Index via Mexameter® MX 18
Measured: From Baseline to 24-hour after product repeat application
Colorimetry (avalue) via Chromameter CM26dG *
Measured: from Baseline to 24-hour after product repeat application
Skin Scaliness (Desquamation) via Squamescan® 850A
Measured: from Baseline to 24-hour after product repeat application
Forearm Skin Redness (avalue) via Cross-Polarized Light Imaging *
The a*value is a parameter in the CIELAB color space (also known as Lab) that quantifies a color's position along the red-green axis .
Measured: From Baseline to 24-hour after product repeat application
Facial Skin Redness and Colorimetry (a* value) via VISIA-CRP Imaging
Measured: from Baseline to 24-hour after product repeat application
Skin Surface Evenness (SEsc) via UV Video Capture and SELS Analysis
Measured: from Baseline to 24-hour after product repeat application
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2025
- Study start15 Jan 2024
- Primary completion22 Jan 2024
- Study completion24 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for RednessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- ChinaNorm
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07200492
- Sponsor's protocol ID
- C23036010
- Status last verified
- Sep 2025
- First submitted
- 11 Sep 2025
- Last updated
- 1 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Anti-Redness Clinical Study
- ClinicalTrials.gov ID
- NCT07200492
- Acronym / sponsor ID
- C23036010
- Conditions
- Redness
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- ChinaNormIndustry (pharma, biotech, devices)
- Study start
- 15 Jan 2024 (actual)
- Primary completion
- 22 Jan 2024 (actual)
- Study completion
- 24 Jan 2024 (actual)
- First posted
- 1 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical study is a single-center, randomized, split-face, on-site controlled trial conducted at Shanghai China-Norm Quality Technical Service Co., Ltd. The primary objective is to evaluate the efficacy of Eucerin Ultrasensitive Repair Intensive Source Serum in providing instant and long-lasting (24-hour) soothing and repairing effects under induced redness conditions. The design involves recruiting 30 healthy Chinese female subjects aged 18-60 years, who meet stringent inclusion/exclusion criteria, including absence of skin conditions and no recent participation in similar studies. Redness is induced using 50% Glycolic Acid on the entire face and tape stripping on both forearms.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Facial Test Arm | Other | Other: Facial serum application |
| Facial Control Arm | No intervention | – |
| Arm Test Arm | Other | Other: Forearm serum application |
| Arm Control Arm | No intervention | – |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Chinese female whose age range from 18 to 60 years old;
- Be in general good health and good mental state;
- Have no any broken,scars,birthmarks and other imperfections on the test area;
- Redness/erythema≥grade 2 after modelling inducing and the score of redness must be increased after inducing;
- Not currently be participating in any other study involving the test area(Face and Forearm);
Key exclusion criteria (16 listed)
- Intending to get pregnant, be pregnant, be lactating, be within 6 months of delivery or be unwilling to take necessary precautions to avoid a pregnancy;
- Having used antihistamine drugs in the past 1 week or immunosuppressants in the past 1 month;
- Taken anti-allergic drug/injections in the past 1 month;
- Presently have allergies, allergic dermatitis or skin disease;
- Have sensitivity or even allergy to topical products, ingredients or fragranced products;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Facial serum applicationThe trained technician will apply the 0.3g-0.4g investigational products on the subject's half face. | Other | Facial Test Arm |
| Forearm serum applicationThe trained technician will apply the (2mg±0.1mg)/cm² investigational products on the subject's forearm. | Other | Arm Test Arm |
Primary outcome
Skin Erythema Index via Mexameter® MX 18
Time frame: From Baseline to 24-hour after product repeat application
Colorimetry (avalue) via Chromameter CM26dG *
Time frame: from Baseline to 24-hour after product repeat application
Skin Scaliness (Desquamation) via Squamescan® 850A
Time frame: from Baseline to 24-hour after product repeat application
Forearm Skin Redness (avalue) via Cross-Polarized Light Imaging *
Time frame: From Baseline to 24-hour after product repeat application
The a*value is a parameter in the CIELAB color space (also known as Lab) that quantifies a color's position along the red-green axis .
Facial Skin Redness and Colorimetry (a* value) via VISIA-CRP Imaging
Time frame: from Baseline to 24-hour after product repeat application
Skin Surface Evenness (SEsc) via UV Video Capture and SELS Analysis
Time frame: from Baseline to 24-hour after product repeat application
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Redness
Enrolling by invitationPhase 4
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
Pyruvate Kinase Deficiency, Anemia, Hemolytic
Active, not recruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period
Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Not yet recruiting
The Effect of 16-week Dietary Intake of Food Supplements Containing Collagen and MSM on Facial Erythema and Other Skin Parameters
Erythema, Telangiectasis
Not yet recruiting
Suture Choice for Ostomy Creation
Ostomy - Ileostomy or Colostomy, Stoma Complications
Active, not recruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period
Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Facial serum application and Forearm serum application in people with Redness, run by ChinaNorm at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Skin Erythema Index via Mexameter® MX 18 (time frame: From Baseline to 24-hour after product repeat application). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2025.